Community Gateway to Health Study
2. juli 2026 opdateret af: Rebekka Lee, Harvard School of Public Health (HSPH)
The goal of this study is to evaluate the impact of a multi-level intervention on cancer prevention and social determinants of health outcomes.
This partnership between academic and community-based researchers aims to link community health centers and communities in ways that maximize both civic engagement and participation in cancer control care.
The system-level intervention consists of two components: (1) provision of community health center systems-level tools for cancer screening (breast, cervical, colorectal) and tobacco cessation treatment gaps; and (2) digital access screening and navigation.
These interventions will be delivered via usual care.
Studieoversigt
Status
Tilmelding efter invitation
Betingelser
Undersøgelsestype
Interventionel
Tilmelding (Anslået)
100
Fase
- Ikke anvendelig
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiesteder
-
-
Massachusetts
-
Boston, Massachusetts, Forenede Stater, 02115
- Harvard TH Chan School of Public Health
-
Springfield, Massachusetts, Forenede Stater, 01103
- Caring Health Center
-
-
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
- Voksen
- Ældre voksen
Tager imod sunde frivillige
Ja
Beskrivelse
Study participants include community health center and community partner staff participating in surveys and interviews about the implementation of the intervention.
Inclusion Criteria:
- Community health center staff or community partners
- Age 18 or older
Exclusion Criteria:
- Under 18
Patients will not be individually recruited for the study because the intervention is being offered as part of routine care.
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Forebyggelse
- Tildeling: Randomiseret
- Interventionel model: Sekventiel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Intervention på flere niveauer
|
This system level intervention consists of two components: (1) provision of community health center systems-level tools for cancer screening (breast, cervical, colorectal) and tobacco cessation treatment gaps; and (2) digital access screening and navigation.
This community level intervention consists of a patient referral from a community health center to a community organization focused on building social capital and civic engagement to test the impact of connecting clinical and community resources explicitly for patients.
|
|
Ingen indgriben: Usual Care
In this stepped wedge design, all sites have a period of being in usual care.
Six sites then have periods of providing the intervention and six sites remain comparison sites (i.e.
usual care).
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Patients Screened for Colorectal Cancer
Tidsramme: change from baseline to end of intervention period, an average of 1 year
|
% patients who are up to date on colorectal cancer screening from EMR
|
change from baseline to end of intervention period, an average of 1 year
|
|
Patients Screened for Breast Cancer
Tidsramme: change from baseline to end of intervention period, an average of 1 year
|
% patients who are up to date on breast cancer screening from EMR
|
change from baseline to end of intervention period, an average of 1 year
|
|
Patients Screened for Cervical Cancer
Tidsramme: change from baseline to end of intervention period, an average of 1 year
|
% patients who are up to date on cervical cancer screening from EMR
|
change from baseline to end of intervention period, an average of 1 year
|
|
Patients Offered Pharmacotherapy for Smoking Cessation
Tidsramme: change from baseline to end of intervention period, an average of 1 year
|
% patients offered pharmacotherapy from EMR
|
change from baseline to end of intervention period, an average of 1 year
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Acceptability of the intervention
Tidsramme: Post intervention, 1 year follow up
|
Self reported via staff survey
|
Post intervention, 1 year follow up
|
|
Feasibility of the intervention
Tidsramme: Post intervention, 1 year follow up
|
Self-reported via staff survey
|
Post intervention, 1 year follow up
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart (Faktiske)
2. juni 2026
Primær færdiggørelse (Anslået)
1. juni 2028
Studieafslutning (Anslået)
1. juli 2029
Datoer for studieregistrering
Først indsendt
4. maj 2026
Først indsendt, der opfyldte QC-kriterier
11. maj 2026
Først opslået (Faktiske)
18. maj 2026
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
6. juli 2026
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
2. juli 2026
Sidst verificeret
1. juli 2026
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- 241740
- U19CA291431 (U.S. NIH-bevilling/kontrakt)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
JA
IPD-planbeskrivelse
Data that underlie the results reported here, after de-identification. Individual staff/partner data on implementation will be made publicly available.
Patient data can be made available upon request and appropriate approvals (see below).
IPD-delingstidsramme
Data will be stored for 7 years.
IPD-delingsadgangskriterier
Outside investigators will need an approved concept proposal to analyze study data and spend the requisite time with study staff to learn about the data elements needed to conduct the proposed analysis.
With the assistance from the study's analytic team, s/he will draft a detailed analysis plan and present to the core group of co-investigators.
The discussion at this meeting ensures adequate knowledge of the data, and the presenter gains much insight into how the analysis can be most useful and how it relates to previous analyses.
Once the plan is approved by this group, it must also be approved by the CHCs that provide the de-identified data.
Following approval by the appropriate IRBs and confirmation that it meets HIPAA requirements, s/he may sign a DUA to use a secure, de-identified dataset to complete only the approved analyses and write the manuscript(s) offsite.
A formal data analysis plan application and DUA are available.
Requests should be directed to jdaly@hsph.harvard.edu.
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Ingen
Studerer et amerikansk FDA-reguleret enhedsprodukt
Ingen
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .